Insights

Expert perspectives, industry outlooks, and success stories from the frontlines of life sciences and healthcare dealmaking and advisory.

All insights

Showing 9 of 22 results
Market outlooks

Lab Automation Software market in the age of Agentic AI

Lab automation software is being rebuilt around AI agents. How an AI native Design-Make-Test-Analyze workflow reshapes the market, and where life sciences software companies should reposition.

Lab informatics and automation
Read 15 November 2026
Biostrat Brief

The process of selling your business – A guide for founders (2/3)

Part 2 of a founder's guide to selling a business: the sale process step by step, from building the buyer funnel to the letter of intent and close, and why deals stall.

M&A
Read 3 November 2026
Biostrat Brief

How to sell your business – A guide for founders (1/3)

Part 1 of a founder's guide to selling a business: the strategic preparation that starts years before an exit, and how a strategic buyer builds its deal case.

M&A
Read 21 October 2026
Biostrat Brief

Frontier AI Is Coming for Bio. Which Moats Survive?

Part 2 of our frontier AI x bio series: the five ways AI x bio moats fail as frontier labs absorb the stack, and the four positions that survive.

Frontier and generative AI
Read 6 October 2026
Biostrat Brief

Life Sciences @ Anthropic, OpenAI, Google, NVIDIA & others AI labs

Part 1 of our frontier AI x bio series: what the labs actually shipped in biology, what has been validated, and why the moat has moved from the model to the loop.

Frontier and generative AI
Read 8 September 2026
Biostrat Brief

The changing wave of AI adoption in pharma: From molecules to models

Pharma has moved from partnering for AI-made molecules to licensing models and owning the capability. Rent, build or buy: how to choose, and what it means for techbio.

AI drug discovery
Read 25 August 2026
Biostrat Brief

What Founders get wrong about the Fundraise

Practical lessons from life sciences fundraises: lead with your strongest card, size the round to the milestone, build a capital stack and read past the headline valuation.

Fundraising
Read 4 August 2026
Biostrat Brief

The Discipline of Engineering a Lucrative Exit

Exits are engineered years before the data room opens. Seven self-inflicted mistakes that quietly kill life sciences deals, and the timeline that avoids them.

M&A
Read 26 July 2026
Biostrat Brief

The Pharma Commercial Services Model that Worked for Decades is Rewiring: Decision Every CEO is now Sitting On

Agentic AI is repricing the seat between pharma's commercial intent and customer behaviour. Which layers of commercial services melt, which survive, and what the deal tape says.

Commercial services
Read 6 July 2026

The BioStrat Brief

A dealmaker's take on M&A, fundraising, strategy and markets in life sciences and healthcare

The BioStrat Brief draws on perspectives and observations gathered through our work. Each new edition is published on LinkedIn.

Read the Brief on LinkedIn

Insights

Expert perspectives, industry outlooks, and success stories from the frontlines of life sciences and healthcare dealmaking and advisory.

All insights

Showing 8 of 22 results
Market outlooks

Lab Automation Software market in the age of Agentic AI

Lab automation software is being rebuilt around AI agents. How an AI native Design-Make-Test-Analyze workflow reshapes the market, and where life sciences software companies should reposition.

Lab informatics and automation
Read 15 November 2026
Biostrat Brief

The process of selling your business – A guide for founders (2/3)

Part 2 of a founder's guide to selling a business: the sale process step by step, from building the buyer funnel to the letter of intent and close, and why deals stall.

M&A
Read 3 November 2026
Biostrat Brief

How to sell your business – A guide for founders (1/3)

Part 1 of a founder's guide to selling a business: the strategic preparation that starts years before an exit, and how a strategic buyer builds its deal case.

M&A
Read 21 October 2026
Biostrat Brief

Frontier AI Is Coming for Bio. Which Moats Survive?

Part 2 of our frontier AI x bio series: the five ways AI x bio moats fail as frontier labs absorb the stack, and the four positions that survive.

Frontier and generative AI
Read 6 October 2026
Biostrat Brief

Life Sciences @ Anthropic, OpenAI, Google, NVIDIA & others AI labs

Part 1 of our frontier AI x bio series: what the labs actually shipped in biology, what has been validated, and why the moat has moved from the model to the loop.

Frontier and generative AI
Read 8 September 2026
Biostrat Brief

The changing wave of AI adoption in pharma: From molecules to models

Pharma has moved from partnering for AI-made molecules to licensing models and owning the capability. Rent, build or buy: how to choose, and what it means for techbio.

AI drug discovery
Read 25 August 2026
Biostrat Brief

What Founders get wrong about the Fundraise

Practical lessons from life sciences fundraises: lead with your strongest card, size the round to the milestone, build a capital stack and read past the headline valuation.

Fundraising
Read 4 August 2026
Biostrat Brief

The Discipline of Engineering a Lucrative Exit

Exits are engineered years before the data room opens. Seven self-inflicted mistakes that quietly kill life sciences deals, and the timeline that avoids them.

M&A
Read 26 July 2026

The BioStrat Brief

A dealmaker's take on M&A, fundraising, strategy and markets in life sciences and healthcare

The BioStrat Brief draws on perspectives and observations gathered through our work. Each new edition is published on LinkedIn.

Read the Brief on LinkedIn

Insights

Expert perspectives, industry outlooks, and success stories from the frontlines of life sciences and healthcare dealmaking and advisory.

All insights

Showing 8 of 22 results
Market outlooks

Lab Automation Software market in the age of Agentic AI

Lab automation software is being rebuilt around AI agents. How an AI native Design-Make-Test-Analyze workflow reshapes the market, and where life sciences software companies should reposition.

Lab informatics and automation
Read 15 November 2026
Biostrat Brief

The process of selling your business – A guide for founders (2/3)

Part 2 of a founder's guide to selling a business: the sale process step by step, from building the buyer funnel to the letter of intent and close, and why deals stall.

M&A
Read 3 November 2026
Biostrat Brief

How to sell your business – A guide for founders (1/3)

Part 1 of a founder's guide to selling a business: the strategic preparation that starts years before an exit, and how a strategic buyer builds its deal case.

M&A
Read 21 October 2026
Biostrat Brief

Frontier AI Is Coming for Bio. Which Moats Survive?

Part 2 of our frontier AI x bio series: the five ways AI x bio moats fail as frontier labs absorb the stack, and the four positions that survive.

Frontier and generative AI
Read 6 October 2026
Biostrat Brief

Life Sciences @ Anthropic, OpenAI, Google, NVIDIA & others AI labs

Part 1 of our frontier AI x bio series: what the labs actually shipped in biology, what has been validated, and why the moat has moved from the model to the loop.

Frontier and generative AI
Read 8 September 2026
Biostrat Brief

The changing wave of AI adoption in pharma: From molecules to models

Pharma has moved from partnering for AI-made molecules to licensing models and owning the capability. Rent, build or buy: how to choose, and what it means for techbio.

AI drug discovery
Read 25 August 2026
Biostrat Brief

What Founders get wrong about the Fundraise

Practical lessons from life sciences fundraises: lead with your strongest card, size the round to the milestone, build a capital stack and read past the headline valuation.

Fundraising
Read 4 August 2026
Biostrat Brief

The Discipline of Engineering a Lucrative Exit

Exits are engineered years before the data room opens. Seven self-inflicted mistakes that quietly kill life sciences deals, and the timeline that avoids them.

M&A
Read 26 July 2026

The BioStrat Brief

A dealmaker's take on M&A, fundraising, strategy and markets in life sciences and healthcare

The BioStrat Brief draws on perspectives and observations gathered through our work. Each new edition is published on LinkedIn.

Read the Brief on LinkedIn